Multiple genetic changes occur in human carcinogenesis, including the activation of proto-oncogenes and inactivation of tumour-suppressor genes . Oncogenes were originally identified in oncogenic retroviruses and in tumour DNA that could transform NIH3T3 cells, and therefore have positive roles in tumorigenesis. On the other hand, tumour-suppressor genes are associated with transformation through the loss of normal gene function and therefore have negative roles in tumorigenesis. Several tumour-suppressor genes have been identified including RB (retinoblastoma), p53, WTI (Wilms' tumour), NFI (neurofibromatosis type 1), DCC (deleted in colon carcinoma), APC (adenomatous polyposis coli), MCC (mutated in colorectal cancer) and VHL (von Hippel-Lindau) (Knudson, 1993) . The mechanisms of inactivation of these tumoursuppressor genes include allelic loss, chromosomal rearrangements, loss of messenger RNA expression, loss of decreased expression of the gene product, point mutation or interaction with the viral or cellular inactivating proteins.
The DCC gene was identified at chromosome 18q21, where allelic deletions frequently occur in colorectal cancers.
Genetic alterations of the DCC gene, including a homozygous deletion of the 5' end of the gene, a point mutation within one of the introns and a DNA insertion at the introns, have also been identified . It was shown recently that the DCC gene spans nearly 1.4 megabases, which makes it the largest tumour-suppressor gene identified so far, and consists of 29 exons . The sequence of DCC cDNA predicts a 1447 amino acid transmembrane protein with four immunoglobulin-like and six fibronectin type III-like extracellular domains . The 325 amino acid cytoplasmic domain has little homology with previously characterised proteins . While (Mesnil et al., 1993) . The role of this gene as a tumour suppressor was demonstrated by the observation that Rat-l fibroblasts in which DCC expression is down-regulated by antisense RNA show a faster growth rate, anchorage independence and tumorigenicity in nude mice (Narayanan et al., 1992) . The introduction of chromosome 18, on which the DCC gene is located, into a human colon carcinoma cell line, COKFu, which does not express DCC gene, results in suppression of tumorigenicity of these cells in athymic nude mice and inhibition of growth in soft agar (Tanaka et al., 1991) , which are consistent with the activity of a tumour-suppressor gene. The tumorigenicity of another colon carcinoma cell line, SW480.7, is also suppressed by the incorporation of chromosome 18 (Goyette et al., 1992) .
Allelic loss of the DCC gene has frequently been observed not only in colorectal carcinomas but also in gastric (Uchino et al., 1992) , oesophageal (Huang et al., 1992) , breast (Devilee et al., 1991) and prostatic carcinomas (Gao et al., 1993) . Expression of the DCC gene has been detected in many normal tissues, including brain and colonic mucosa , while its expression is absent or greatly reduced in colorectal (Itoh et al., 1993) , pancreatic (H6hne et al., 1992) and prostatic carcinomas (Gao et al., 1993) and malignant gliomas (Scheck and Coons, 1993 . For an internal control of RT-PCR, a 319bp fragment of P-actin was simultaneously amplified using primers 5'-ATCATGmTTGAGACCI-TCAA-3' and 5'-CATCTCTTGCTCGA-AGTCCA-3' (Fuqua et al., 1990) . The PCR mixture (total 50 il) contained cDNA (200-500 ng), 0.5 pm of each primer for DCC, 0.05 gIM of each primer for P-actin, 100 gIM of each deoxynucleotide triphosphate, 0.5 U of Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA), 1.5 mM magnesium chloride, 50 mM potassium chloride, 1O mM Tris-HCI (pH 8.3) and 0.01 % gelatin. One cycle consisted of 1 min at 94-C (denaturation), 1 min at 55C (annaling) and 1 min at 72-C (elongation) and a total of 28 cycles of PCR amplification was performed. The PCR products were fractionated in 12% polyacrylamide gels, and DNA fragments were visualised by staining with ethidium bromide. Quantitation was done by densitometric analysis using the software NIH Image version 1.44.
Immunohistochemistry
The tissue localisation of DCC protein was determined immunohistochemically by the avidin-biotin-peroxidase complex method on frozen sections. Sections (4 pm) were cut with a cryostat, placed on glass slides coated with 0.02% poly-L-lysine (Sigma, St Louis, MO, USA), and fixed with acetone for 10 min at room temperature. The sections were immersed in 0.3% hydrogen peroxidase to block endogenous peroxidase activity, and the staining procedures were then s u T Enorr et al 463 carried out according to the manufacturer's recommendation (Vector Laboratories, Buringhame, CA, USA). A monoclonal antibody to the DCC gene product (Ab-1) (Oncogene Science, Uniondale, NY, USA) was used as primary antibody for the present immunohistochemistry. Sections from normal proliferative endometrium and normal ovary were used as positive controls for the expression of DCC. Sections on which normal mouse serum were incubated instead of the corresponding primary antibody were used as negative controls. The relative number of immunoreactive cells was graded from negative to grade 3 (+ + +) as follows. (-, -no staining was observed in any tumour cell; +, less than 10% of the tumour cells were stained positively, + +, between 10% and 50% of the tumour cells were stained positively, + + +, more than 50% of the tumour cells were stained positively.)
Detection of loss of heterozygosity by PCR-RFLP analysis PCR amplification was performed to generate 367 bp DNA fragments around the polymorphic MspI sites of the DCC gene. The PCR mixture was prepared from a GeneAmp DNA amplification reagent kit (Perklin-Elmer Cetus) following the manufacturer's instructions. Primers used were 5'-TTGCACCATGCTGAAGATTCTT-3' (upstream) and 3'-ATTTCAGTAGTCCCCCTCCCA-5'(downstream) (Parry et al., 1991) . DNA (SOOng) was added to the 50id reaction mixture and incubated initially for 5 min at 100-C. Then 0.25 units of Taq polymerase was added. One cycle consisted of I min at 95-C (denaturation), I min at 59 C (annealing) and 1 min at 72 C (elongation) and a total of 35 cycles of PCR amplification were performed. A 10Il aliquot of this PCR product was digested with 100 U of the restriction endonuclease MspI (Toyobo, Japan) at 3rC for 6 h and electrophoresed in a 12% non-denaturing polyacrylamide gel. DNA fragments were visualised by staining with ethidium bromide. The amplified 367 bp fragment was cut into 227 bp and 140 bp fragments when the restriction site was present. Cases in which DNA derived from white blood cells (WBCs) yielded three fragments (367 bp, 227 bp and 140 bp) were considered informative, and DNA derived from the tumours was further analysed for loss of heterozygosity. in none of two (0%), one of two (50%) and three of four (75%) endometrial carcinomas of grade 1, 2 and 3, respectively, and one of seven (14%), two of six (33%) and all seven (100%) ovarian epithelial tumours of grade 1, 2 and 3 respectively (Table H) . The prevalence of impaired DCC expression in grade 3 ovarian epithelial tumours was significantly higher than that in grade 1 tumours (P =0.002 by Fisher's exact test). Therefore reduced or absent expression of the DCC gene tended to occur in tumours of higher histological grade. In the ovary, decreased or loss of expression was found more frequently in serous tumours (7/10, 70%) than in mucinous tumours (1/6, 17%).
Immuzohistochemical detection of the DCC gene product The DCC gene product was examined immunohistochemically in five endometrial adenocarcinomas and 13 ovarian (Figure 3 ). Even in a single tumour, staining intensity varied from area to area, although there was a tendency that it was less evident in areas of histologically more aggressive lesion. Four of five endometrial carcinomas and 5 of 13 ovarian adenocarcinomas showed negative staining (Table I) . Three endometrial adenocarcinomas (cases 4, 7 and 8) and four ovarian adenocarcinomas (cases 2, 6, 9 and 19) which showed negative staining did not express DCC mRNA. Two ovarian adenocarcinomas which showed weak positive staining (cases 3 and 7) revealed reduced DCC mRNA expression. The intensity of the immunohistochemical staining correlated significantly with the level of mRNA expression in ovarian tumours (P = 0.01 by chi-square test) or in both endometrial carcinomas and ovarian tumours combined (P = 0.001 by chisquare test). Although a single case of endometrial carcinoma (case 5) and a single case of ovarian adenocarcinoma (case 12) showed no stg in spite of positive DCC mRNA expression, there was, thus, a sigicant correlation between the mRNA expression and immunohistochemistry.
Detection of loss ofheterozygosity in the DCC gene Loss of heterozygosity in the DCC gene was detected by PCR-(RFLP) analysis (Figure 4) . Of a total of 102 samples analysed, DNA derived from WBCs or the histologically normal tissue from 7 of 32 (22%) endometrial adenocarcinomas, one of seven (14%) endometrial atypical hyperplasias, 11 of 29 (38%) cervical carcinomas and 6 of 34 (18%) ovarian tumours showed heterozygosity and were therefore informative for the LOH analysis. (Nigro et al., 1989; Levine et al.. 1991) . Mutations of both p53 alleles, one through deletion and the other through a base substitution, occur in many human cancers including endometrial carcinoma (Okamoto et al., 1991a; Enomoto et al., 1993b) and ovarian carcinoma (Mazars et al., 1991; Okamoto et al., 1991b) . The mechanism of inactivation of the RB tumour-suppressor gene seems to be different from that of the p53 gene. There is no correlation between the loss of expression of the RB protein and loss of heterozygosity of the RB gene in bladder carcinoma (Ishikawa et al., 1991) and breast cancer (Borg et al.. 1992) . We previously reported that loss of heterozygosity does not accompany loss of mRNA expression in an endometrial carcinoma (Enomoto et al., 1993a 
